← Back to news
NewsKIDNEY INTERNATIONALSaturday, February 21, 2026 · February 21, 2026

Modern challenges in infection prevention: encapsulated organisms in the era of novel complement inhibitors.

WHY IT MATTERS

Recent peer-reviewed research on Atypical hemolytic uremic syndrome that may be relevant for patients and caregivers.

Complement inhibitors are now approved for use in atypical hemolytic uremic syndrome, IgA nephropathy, and C3 glomerulopathy. They are being studied widely in kidney disease, and more indications may soon arise. This review addresses an approach to preventing infectious complications, particularly e...

Read on PubMed
Read the original at Kidney international
ResearchPubMedAtypical hemolytic uremic syndromeHumansComplement Inactivating Agents

Related conditions

Atypical hemolytic uremic syndrome

Related news

Int J Circumpolar Health · -222 days ago
A population-based legacy study of myasthenia gravis in Iceland: insights from a small Arctic nation
Published in Int J Circumpolar Health. Hjaltason H et al.
Ther Adv Rare Dis · -192 days ago
Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy
Published in Ther Adv Rare Dis. Mitha A et al.
Health Inf Sci Syst · -192 days ago
PhenoRareAI: Phenotype-based intelligent diagnosis for rare neuromuscular disorders of glycogen storage disease and spinal muscular atrophy
Published in Health Inf Sci Syst. Zhai W et al.
J Allergy Clin Immunol Glob · -39 days ago
Emerging trends and research hot spots in inborn error of immunity: A bibliometric perspective
Published in J Allergy Clin Immunol Glob. Alblooshi H et al.